The Future of CAR-T
July 23, 2026Core Framework & Diagram The Future of Cancer Vaccines
July 24, 2026
The Future of Cancer Vaccines
Cancer vaccines are no longer only about prevention — they're becoming weapons of treatment
By the Editors 1-min read
When most people hear 'cancer vaccine,' they think of HPV vaccine — get vaccinated, prevent cervical cancer. This is cancer vaccines' earliest, most mature form: preventive vaccines, blocking carcinogenic viruses before cancer occurs.
But cancer vaccines' ambition is far greater.
Second generation: therapeutic vaccines — after cancer has already occurred, using vaccines to activate the immune system to attack existing tumor cells.
Third generation: individualized mRNA cancer vaccines — reading out your tumor's unique mutations, synthesizing a vaccine exclusively for you, activating immune responses targeting only your cancer cells. This isn't science fiction — 2023 clinical trial data has already shown real, exciting effects.
Cancer vaccines' future is a continuous evolution from 'prevention' to 'treatment' to 'individualization.'
KEY TAKEAWAYS
01
Cancer vaccines have evolved through three generations: preventive (HPV/HBV vaccines, commercially mature) → therapeutic universal type (Sipuleucel-T, concept proven) → individualized mRNA neoantigen vaccines (2023 Phase 2 data breakthrough).
02
HPV vaccine is one of the most successful cancer prevention tools; Australia is expected to eliminate cervical cancer by 2028. Improving Asian vaccine coverage rates remains an important task.
03
mRNA-4157 (Moderna+Merck) Phase 2 data: combined with Pembrolizumab, reduces high-risk melanoma recurrence/death risk by forty-four percent, three-year recurrence-free survival improved to 74.8% — the strongest clinical evidence for individualized cancer vaccines.
04
Cancer vaccine + PD-1 inhibitor is the golden combination: vaccine 'summons more soldiers,' PD-1 inhibitor 'removes soldiers' shackles' — both target different bottlenecks on the same causal chain, synergistic rather than competing.
05
Next frontier: preventive intervention at pre-cancerous lesion/high-recurrence-risk stages (MGUS, BRCA carriers), and ctDNA-guided ultra-early cancer vaccination — from treatment toward truly becoming prevention.
06
2030 outlook: individualized mRNA vaccine manufacturing time from weeks compressed to days, cost from hundreds of thousands to tens of thousands, becoming standard adjuvant treatment options for multiple solid tumors.
Art 145
The Future of Immunotherapy
→
Art 146
The Future of Immune Rejuvenation
→
